IP Library › Granted Patent US 12,414,558
Granted Patent B2
US 12,414,558 · App. 18/107,320 · Granted Sep 16, 2025

Method for administering umbilical cord blood or peripheral blood

Inventors: Minoko Takanashi (Tokyo, JP); Miyuki Ito (Tokyo, JP); Kohichi Saze (Fukushima, JP)
Assignees: JAPANESE RED CROSS SOCIETY; ZENOGEN PHARMA CO., LTD.
A01N1/125A01N1/162A61K35/14A61K35/51C12N5/0634
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,414,558
App. No.
18/107,320
Granted
Sep 16, 2025
Kind
B2
Abstract

An object of the present invention is to provide (i) a cryopreservation solution which can be used for cryopreserving umbilical cord blood, peripheral blood, and a component containing hematopoietic stem cells derived from any one of these types of blood and which has characteristics suitable for various utilization forms and (ii) use of the cryopreservation solution. In a cryopreservation method in accordance with the present invention, a cryopreservation solution containing a cryoprotectant and glucose is mixed with umbilical cord blood or peripheral blood, and a mixture thus obtained is frozen.

Claims (13)

1. A method for administering umbilical cord blood or peripheral blood, comprising:

a cryopreservation step of cryopreserving a mixture of (i) a cryopreservation solution and (ii) umbilical cord blood or peripheral blood to obtain cryopreserved material;

a thawing step of thawing the cryopreserved material obtained in the cryopreservation step; and

an administration step of administering, to a living body, the umbilical cord blood or peripheral blood and the cryopreservation solution that are thawed in the thawing step,

the cryopreservation solution containing dimethyl sulfoxide and glucose, and containing no thickener and no dextran,

wherein the umbilical cord blood or the peripheral blood contains stem cells, and

wherein the mixture contains the dimethyl sulfoxide in an amount of 3.0 w/v % to 5.0 w/v % and the glucose in an amount of 1.5 w/v %.

2. The method as set forth in claim 1 , wherein the cryopreservation solution contains no animal-derived natural component.

3. The method as set forth in claim 1 , wherein in the mixture, the volume ratio of the cryopreservation solution to the umbilical cord blood or peripheral blood is 1:1 to 3:1.

4. The method as set forth in claim 1 , wherein the umbilical cord blood or the peripheral blood is one from which at least part of red blood cells has been removed.

5. The method as set forth in claim 1 , wherein the umbilical cord blood or the peripheral blood is derived from a human.

6. The method as set forth in claim 1 , wherein the administration is carried out with respect to a human.

7. The method as set forth in claim 1 , wherein the living body is a human in need of a transplant of cells contained in the umbilical cord blood or peripheral blood.

Assignments (2)
CHANGE OF NAME Recorded Feb 10, 2023
From: ZENOAQ RESOURCE CO., LTD.
To: ZENOGEN PHARMA CO., LTD.
Reel/Frame 062655/0808 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2023
From: TAKANASHI, MINOKO; ITO, MIYUKI; SAZE, KOHICHI
To: JAPANESE RED CROSS SOCIETY; ZENOAQ RESOURCE CO., LTD.
Reel/Frame 062635/0862 →
Priority Claims (2)
JP 2014-232211 · Nov 14, 2014 · national
JP 2015-121460 · Jun 16, 2015 · national
Continuity (2)
Continuation 15526175
Related Publication 20230180740A1 · Jun 15, 2023
References Cited (47)
US 6869758B1 · Gao · 2005 [cited by applicant]
US 20040241183A1 · Hasumi · 2004 [cited by applicant]
US 20050026133A1 · Nakatsuji · 2005 [cited by applicant]
US 20060188984A1 · Rudd · 2006 [cited by applicant]
US 20060193839A1 · Rudd · 2006 [cited by applicant]
US 20090104650A1 · Walton · 2009 [cited by applicant]
US 20090142830A1 · Yamashiro et al. · 2009 [cited by applicant]
US 20130095079A1 · Bernstein · 2013 [cited by examiner]
US 20130280805A1 · Pogue et al. · 2013 [cited by applicant]
US 20150320031A1 · Andreasen · 2015 [cited by applicant]
US 20160008408A1 · Imagawa et al. · 2016 [cited by applicant]
US 20190000070A1 · De Larichaudy · 2019 [cited by examiner]
CA 2597963 · 2009 [cited by applicant]
JP 2008237136 · 2008 [cited by applicant]
JP 2014113166 · 2014 [cited by applicant]
JP 2015142559 · 2015 [cited by applicant]
JP 2016501873 · 2016 [cited by applicant]
KR 100953400 · 2010 [cited by applicant]
WO 9300807 · 1993 [cited by applicant]
WO 2006130812 · 2006 [cited by applicant]
WO WO2014053420A1 · 2014 [cited by examiner]
WO 2014142038 · 2014 [cited by applicant]
WO 2015062267 · 2015 [cited by applicant]
WO 2015150394 · 2015 [cited by applicant]
Djerassi, I et al. Preparation and in vivo circulation of human platelets preserved with combined dimethylsulfoxide and dextrose. Transfusion. 1966. 6(6): 572-576. (Year: 1966). [cited by examiner]
Balci, D et al. The assessment of cryopreservation conditions for human umbilical cord stroma-derived mesenchymal stem cells towards a potential use for stem cell banking. Current Stem Cell Research & Therapy. Jan. 2013… [cited by examiner]
Holm, F et al. An effective serum- and xeno-free chemically defined freezing procedure for human embryonic and induced pluripotent stem cells. Human Reproduction. 2010. 25(5): 1271-1279. (Year: 2010). [cited by examiner]
International preliminary report on patentability of PCT/JP2015/082034, mailed May 16, 2017, 9 pages. [cited by applicant]
Takanashi et al. “Red blood cell depletion of cord blood using an automated system—Evaluation of the AXP system.” Japanese Journal of Transfusion and Cell Therapy, vol. 56, No. 1 56(1):62-67, 2010. [cited by applicant]
Ito Miyuki et al. P1-3 Evaluation of a New Cryoprotectant; “Improved Stem-Cellbanker” Programs and Abstracts for the 37th Annual Meeting of the Japan Society for Hematopoietic Cell Transplantation, p. 243, Feb. 2015. [cited by applicant]
Ito Miyuki et al. P1-133 Concentration of Dimethylsulfoxide to Be Used for Cord Blood Cryopreservation, Programs and Abstracts for the 35th Annual Meeting of the Japan Society for Hematopoietic Cell Transplantation, p. … [cited by applicant]
Yamaguchi R, Takanashi M, Ito M, et al. “Plasticizer concentration in cord blood cryopreserved with DMSO” Bone Marrow Transplantation, vol. 49, pp. 157-158, 2014. [cited by applicant]
International Search Report for PCT/JP2015/082034, mailed Jan. 26, 2016, 2 pages. [cited by applicant]
Holm, F. et al: “An effective serum- and xeno-free chemically defined freezing procedure for human embryonic and induced pluripotent stem cells”, Human Reproduction, vol. 25, No. 5, Mar. 5, 2010 Mar. 5, 2010), pp. 1271-… [cited by applicant]
EP Search Report, EP Patent Application No. 15859595.9, mailed Oct. 13, 2017. [cited by applicant]
Office Action, JP Patent Application No. 2016-559123, mailed Jan. 23, 2018. [cited by applicant]
Quan, GB et al. Effects of pre-freeze incubation of human red blood cells with various sugars on posthaw recovery when using a dextran-rapid cooling protocol. Cyrobiology, 2009. 59: 258-267. [cited by applicant]
Rodrigues, JP et al. Evaluation of trehalose and sucrose as cryoprotectants for hermatopoietic stem cells of umilibilical cord blood. Cryobiology. 2008. 56: 144-151. [cited by applicant]
Clark, P et al. Factors influencing renal cryopreservation. II. Toxic effects of three cryoprotectants in combination with three vehicle solutions in nonfrozen rabbit cortical slices. Cryobiology. 1984. 21: 274-284. [cited by applicant]
Requirement for Restriction / Election, U.S. Appl. No. 15/526,175, mailed Nov. 2, 2018. [cited by applicant]
Non-Final Rejection, US Patent Application No. 15/526, 175, mailed Mar. 7, 2019, available in PAIR. [cited by applicant]
Final Rejection, U.S. Appl. No. 15/526,175, mailed Sep. 3, 2019. [cited by applicant]
Non-Final Rejection, U.S. Appl. No. 15/526,175, mailed Apr. 6, 2020. [cited by applicant]
Non-Final Rejection, U.S. Appl. No. 15/526,175, mailed Oct. 5, 2020. [cited by applicant]
Final Rejection, U.S. Appl. No. 15/526,175, mailed Jul. 6, 2021. [cited by applicant]
Non-Final Rejection, U.S. Appl. No. 15/526,175, mailed Mar. 31, 2022. [cited by applicant]
Final Rejection, U.S. Appl. No. 15/526,175, mailed Nov. 14, 2022. [cited by applicant]